The Neuroimmunology Drugs Market is valued at 21.84 Billion in 2022 and is predicted to reach 41.48 Billion by the year 2031 at a 7.55 % CAGR during the forecast period for 2023-2031.
Neuroimmunology includes applied and fundamental biology, immunology, neurology, chemistry, pathology, virology, and psychiatry of the central nervous system (CNS). The study of communications of the nervous system and immune is known as neuroimmunology. The development of the drug in neuroimmunology is anticipated to witness robust growth in the global market. The advancements in neurogenetics, fundamental pathology of the numerous diseases, and targeted therapy mechanism for drug development are some of the key factors boosting the neuroimmunology drugs market globally. The presence of a large number of drugs in clinical stages for the treatment of neuroimmunology diseases such as Multiple Sclerosis (MS), and Alzheimer’s disease (AD) is expected to generate immense opportunity for the market in the coming years. Additionally, numerous strategies opted by companies to develop advanced treatment options such as studying different targets for drug acting.
Small molecule and mAbs are the most common type of molecule in neuroimmunology, as they penetrate the blood-brain barrier. The high prevalence of neuroimmunology disease globally is expected to boost the demand for the drugs market in the coming years. According to the National MS Society, in 2019 about one million people living in the U.S. were suffering from multiple sclerosis. The number is twice of people suffering in 1975. The growing prevalence of neuroimmunology diseases is expected to generate substantial demand for advanced treatment options globally. However, the high cost associated with mAbs based therapy may hinder market growth significantly. However, research and development activities among research universities, hospitals, and companies operating in the market are projected to generate immense opportunities for the growth of the market globally.
Market Segmentation
The Global Neuroimmunology Drugs Market is segmented on the basis of indication, target type, and region. Based on the indication, the neuroimmunology drugs market is divided into Multiple Sclerosis (MS), Alzheimer’s disease (AD), and Others. The wide range of pipeline drugs for these indications are expected to boost the segmental growth during the estimated timeframe. The market is segmented into Cytokines, Lymphocytes or Molecules Associated with their Activation or Migration, and Others based on target type. The cytokines is the most common receptor for pipeline drugs of multiple sclerosis. About 35% of pipeline drugs for MS are targeting cytokine receptors. On the basis of the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. The Asia Pacific is estimated to register high growth in the neuroimmunology drugs market during the estimated timeframe.
Competitive Landscape
Some major key players in the Neuroimmunology Drugs Market:
- Hoffmann-La Roche Ltd,
- Biogen,
- AstraZeneca Plc,
- T3D Therapeutics,
- Johnson & Johnson,
- Merck KGaA,
- Celgene Corp.,
- Novartis AG,
- Sanofi,
- UCB SA,
- Eisai Co Ltd,
- Eli Lilly,
- Tiaki Therapeutics,
- AB Science S.A.,
- ImmunoBrain Checkpoint,
- Actelion Pharmaceuticals Ltd.,
- AstronauTx,
- Alector,
- AZTherapies Inc.,
- INmune Bio, Inc.,
- Lundbeck,
- Genetech Inc.,
- Grifols SA,
- G. Therapeutics Inc.,
- Talisman Therapeutics,
- AevisBio Inc.,
- Monument Tx,
- Inflammasome Therapeutics,
- TauRX Therapeutics Ltd
- Others
The Neuroimmunology Drugs Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 21.84 Million |
|
Revenue Forecast In 2031 |
USD 41.48 Million |
|
Growth Rate CAGR |
CAGR of 7.55 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Indication, By Product Type |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
F. Hoffmann-La Roche Ltd, Biogen, AstraZeneca Plc, T3D Therapeutics, Johnson & Johnson, Merck KGaA, Celgene Corp., Novartis AG, Sanofi, UCB SA, Eisai Co Ltd, Eli Lilly, Tiaki Therapeutics, AB Science S.A., ImmunoBrain Checkpoint, Actelion Pharmaceuticals Ltd., AstronauTx, Alector, AZTherapies Inc., INmune Bio, Inc., Lundbeck, Genetech Inc., Grifols SA, T.G. Therapeutics Inc., Talisman Therapeutics, AevisBio Inc., Monument Tx, Inflammasome Therapeutics, and TauRX Therapeutics Ltd among others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
